Abionic is focused on delivering true patient-centric point-of-care (near-patient) testing solutions available instantly at any time, from anywhere, whenever a patient needs it.
Abionic has developed an unparalleled nanofluidic technology-based diagnostic platform, combining nanoengineering, biochemical and medical sciences, to offer patients the fastest test results.
By bringing together the ultra-rapid diagnostic platform and the Pancreatic Stone Protein (PSP) biomarker, Abionic’s unique PSP Sepsis Test enables healthcare professionals to detect sepsis in just 5 minutes and up to 72h before the Standard of Care, with the potential to save millions of lives
How many organisations/clients currently utilise the service/solution across the UK?
The abioSCOPE and the IVD CAPSULE PSP (Pancreatic Stone Protein) have been used in 3 hospitals in the UK (University College Hospital London, Royal Surrey County Hospital, Guildford and Guy’s and St Thomas’ Hospital, London) in the context of a 14 centres study to assess the potential of serial PSP measurements for the early recognition of sepsis in patients hospitalized in the intensive care unit (ICU). This study highlights the primary advantage of PSP over canonical markers (as PCT and CRP), being that it increases early in the course of sepsis development.
Is there anything you would like to make delegates aware of ahead of the Managing Deteriorating Conditions Conference on 12th October?
Abionic’s abioSCOPE is the fastest and most versatile diagnostic platform existing on the market today. Thanks to our patented technology, we provide quantitative results in just a few minutes with a single drop of blood. Our early sepsis biomarker is backed up by significant clinical evidences and more tests will be launched on the market in the coming months covering a wide range of clinical applications. Abionic’s products are currently commercialized in more than 32 countries around the globe and used in many hospitals for early sepsis identification.
What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
Our system is a point-of-care that is designed to be used at the bedside of the patient. The collaboration of departments and laboratory is key.
Do you want to add any other key points?
We are eager to expand our presence in the UK. If you are interested to know more do not hesitate to contact us at firstname.lastname@example.org.